EFFECT ·Filed Apr 15, 2026

LYEL

Lyell Immunopharma, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC9999999995-26-001185
IPO/offering going effective
Actionable Insight • Neutral

Traders should monitor for potential secondary sales by institutional holders, which could increase near-term share supply and pressure stock price; however, no immediate dilution or capital raise by the company is occurring.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
LYEL ▼ -37.04% at T+60d
NEUTRAL call ✗ call lost -37.04% · α vs SPY -45.18% · entry $23.84 → $15.01
Entry anchored
Apr 14, 03:59 PM ET
via exchange tick
T+1d
-0.59%
call -0.59% · α -0.84%
$23.70
settled 6mo ago
T+5d
+3.94%
call +3.94% · α +2.30%
$24.78
settled 5mo ago
T+20d
-19.25%
call -19.25% · α -25.30%
$19.25
settled 5mo ago
T+60d
-37.04%
call -37.04% · α -45.18%
$15.01
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Lyell Immunopharma's S-3 shelf registration has become effective, allowing the resale of up to 1,952,360 shares by selling stockholders. The company will not receive proceeds from any sales under this registration.

Key Facts

  • S-3 shelf registration effective as of April 14, 2026
  • Enables resale of 1,952,360 shares of common stock by selling stockholders
  • Shares were acquired in a private placement on March 6, 2026, at $25.61 per share
  • Company will not receive any proceeds from resales under this registration
  • Selling stockholders include institutional investors such as ARCH Venture Fund, Gates Frontier, and Explore Investments

Financial Impact

No direct financial impact to Lyell Immunopharma — no proceeds from resales

dilutionshareholder structure

Risk Factors

  • Potential for increased share volatility if selling stockholders offload large positions
  • Perception of negative sentiment if early investors begin exiting positions

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001185
Document: 9999999995-26-001185-index.html9999999995-26-001185
Document: 9999999995-26-001185.txt9999999995-26-001185
13 reports for LYEL
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for LYEL — sortable, filterable
TypeNow
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 4/10
$15.49 $10.53▼ −32.02%▼ −33.00%$9.26 (−40.22%)
Jul 22, 2026
10w ago
EFFECT
NEUTRAL ★ 4/10
$12.84 $15.76▲ +22.74%▲ +19.84%$9.26 (−27.88%)
Jun 15, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$12.44 $13.40▲ +7.72%▲ +7.52%$9.26 (−25.56%)
Jun 12, 2026
16w ago
Press Release
NEUTRAL ★ 4/10
$13.50 $15.01▲ +11.19%▲ +9.41%$9.26 (−31.41%)
Jun 8, 2026
16w ago
Press Release
BULLISH ★ 7/10
$12.31 $14.04▲ +14.05%▲ +12.42%$9.26 (−24.78%)
Jun 4, 2026
17w ago
Press Release
NEUTRAL ★ 3/10
$11.97 $14.04▲ +17.29%▲ +15.43%$9.26 (−22.64%)
Apr 24, 2026
23w ago
DEFA14A
NEUTRAL ★ 3/10
$22.62 $16.37▼ −27.63%▼ −32.59%$9.26 (−59.06%)
Apr 15, 2026
24w ago
EFFECT
NEUTRAL ★ 2/10
$23.84 $19.25▼ −19.25%▼ −25.30%$9.26 (−61.16%)
Apr 3, 2026
26w ago
S-3
NEUTRAL ★ 2/10
$21.69 $20.72▼ −4.47%▼ −13.45%$9.26 (−57.31%)
Mar 12, 2026
29w ago
Press Release
MIXED ★ 6/10
$21.25 $24.80▲ +16.71%▲ +13.12%$9.26 (−56.42%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (65h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access